XYZAL Drug Patent Profile
✉ Email this page to a colleague
When do Xyzal patents expire, and what generic alternatives are available?
Xyzal is a drug marketed by Chattem Sanofi and is included in four NDAs. There is one patent protecting this drug and two Paragraph IV challenges.
The generic ingredient in XYZAL is levocetirizine dihydrochloride. There are thirteen drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the levocetirizine dihydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xyzal
A generic version of XYZAL was approved as levocetirizine dihydrochloride by SYNTHON PHARMS on November 26th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XYZAL?
- What are the global sales for XYZAL?
- What is Average Wholesale Price for XYZAL?
Summary for XYZAL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 66 |
Patent Applications: | 150 |
Drug Prices: | Drug price information for XYZAL |
Drug Sales Revenues: | Drug sales revenues for XYZAL |
What excipients (inactive ingredients) are in XYZAL? | XYZAL excipients list |
DailyMed Link: | XYZAL at DailyMed |
![XYZAL drug patent expirations Drug patent expirations by year for XYZAL](/p/graph/s/t/XYZAL-patent-expirations.png)
![Drug Prices for XYZAL](/p/graph/drug-price/XYZAL.png)
![Drug Sales Revenue Trends for XYZAL](/p/graph/drug-sales-revenues/XYZAL.png)
Paragraph IV (Patent) Challenges for XYZAL
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
XYZAL | Oral Solution | levocetirizine dihydrochloride | 0.5 mg/mL | 022157 | 1 | 2009-01-14 |
XYZAL | Tablets | levocetirizine dihydrochloride | 5 mg | 022064 | 1 | 2007-12-17 |
US Patents and Regulatory Information for XYZAL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chattem Sanofi | XYZAL | levocetirizine dihydrochloride | SOLUTION;ORAL | 022157-001 | Jan 28, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chattem Sanofi | XYZAL ALLERGY 24HR | levocetirizine dihydrochloride | TABLET;ORAL | 209089-001 | Jan 31, 2017 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chattem Sanofi | XYZAL | levocetirizine dihydrochloride | TABLET;ORAL | 022064-001 | May 25, 2007 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chattem Sanofi | XYZAL ALLERGY 24HR | levocetirizine dihydrochloride | SOLUTION;ORAL | 209090-001 | Jan 31, 2017 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XYZAL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chattem Sanofi | XYZAL | levocetirizine dihydrochloride | SOLUTION;ORAL | 022157-001 | Jan 28, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Chattem Sanofi | XYZAL | levocetirizine dihydrochloride | TABLET;ORAL | 022064-001 | May 25, 2007 | ⤷ Sign Up | ⤷ Sign Up |
Chattem Sanofi | XYZAL | levocetirizine dihydrochloride | TABLET;ORAL | 022064-001 | May 25, 2007 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XYZAL
See the table below for patents covering XYZAL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Latvia | 5494 | 2-Ú4-(difenilmetil)-1-piperazinil3⁄4-etikskabes vai to amidi vai to netoksiskie farmaceitiski pielaujamie sali ar spazmolitisku un antihistamina darbibu | ⤷ Sign Up |
Yugoslavia | 42911 | ⤷ Sign Up | |
Austria | 8140 | ⤷ Sign Up | |
Canada | 1199918 | ACIDES 2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL] ACETIQUES ET LEURS AMIDES (2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]-ACETIC ACIDS AND THEIR AMIDES) | ⤷ Sign Up |
Spain | 521548 | ⤷ Sign Up | |
Norway | 2001022 | ⤷ Sign Up | |
Georgia, Republic of | P20001996 | Novel 2-(4-diphenylmethyl)-1-Piperazinyl)-Acetic Acids and their Amides, Process for Their Preparation and Pharmaceutical Compositions | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XYZAL
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0663828 | SPC007/2002 | Ireland | ⤷ Sign Up | SPC007/2002: 20040517, EXPIRES: 20160102 |
0058146 | SPC/GB01/052 | United Kingdom | ⤷ Sign Up | SPC/GB01/052:, EXPIRES: 20070205 |
0663828 | 0490019-7 | Sweden | ⤷ Sign Up | PRODICT NAME: LEVO-CETIRIZIN OCH SALTER DAERAV; NAT REGISTRATION NO/DATE: 20039 20040423; FIRST REGISTRATION: DE 49903.00.00 20010103 |
0663828 | CA 2002 00006 | Denmark | ⤷ Sign Up | |
0663828 | 2002C/005 | Belgium | ⤷ Sign Up | PRODUCT NAME: LEVOCETIRIZIN. DIHYDROCHLORID; NAT. REGISTRATION: 194 IS 90 F 3 20011022; FIRST REGISTRATION: DE 49904.00.00 20010103 |
0663828 | C300085 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
0663828 | 10/2002 | Austria | ⤷ Sign Up | PRODUCT NAME: LEVOCETIRIZIN; NAT. REGISTRATION NO/DATE: 1-24226 20011005; FIRST REGISTRATION: DE 49903.00.00; 49904.00.00 20010103 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |